Phio Pharmaceuticals Corp (PHIO)

$1.08 -0.01 (-0.92%)
Market Cap 12.06M
Revenue (ttm) 0.00
Net Income (ttm) -7.15M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 187,671
Avg Vol 3,629,748
Day's Range N/A - N/A
Shares Out 10.76M
Stochastic %K 6%
Beta 0.92
Analysts Sell
Price Target $14.00

Company Profile

Phio Pharmaceuticals Corp., a a clinical stage biotechnology company, engages in the development of immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells' ability to kill cancer cells; and PH-762 treated double positive tumor infiltrating lymphocytes, which is in Phase 1 clinical trials to treat advanced melanoma a...

Industry: Biotechnology
Sector: Healthcare
Phone: 508 767 3861
Address:
11 Apex Drive, Suite 300A PMB 2006, Marlborough, United States
DosGatos
DosGatos Dec. 16 at 6:37 PM
$PHIO Pumpers gone?
0 · Reply
DosGatos
DosGatos Dec. 16 at 6:37 PM
$PHIO one buck chuck!
0 · Reply
RetiredOldGeezer
RetiredOldGeezer Dec. 16 at 4:09 PM
$PHIO 12/16/25 Status from Clinical.gov site Still Recruiting - i thought that was completed? NCT06014086 Recruiting Intratumoral PH-762 for Cutaneous Carcinoma
0 · Reply
Tiredofbeingpoor
Tiredofbeingpoor Dec. 16 at 12:55 AM
$PHIO I think I’ll keep buying
0 · Reply
DosGatos
DosGatos Dec. 15 at 7:40 PM
$PHIO Below a buck?
1 · Reply
RetiredOldGeezer
RetiredOldGeezer Dec. 15 at 12:53 AM
$PHIO Old Bobby and his 3 babes have abandoned legacy holders - should have seen it coming when they put a wall street shark to head board - dead money but hopefully they are enjoying their our money.
0 · Reply
Stock__Hunter
Stock__Hunter Dec. 12 at 8:01 PM
$OCG pulled a $PHIO On ya
0 · Reply
PitaPierogi
PitaPierogi Dec. 12 at 2:49 PM
$PHIO https://x.com/i/status/1999201934797066382
0 · Reply
RetiredOldGeezer
RetiredOldGeezer Dec. 10 at 5:30 PM
$PHIO Are they still recruiting or was that a little fib?????
0 · Reply
PitaPierogi
PitaPierogi Dec. 9 at 11:26 PM
$PHIO big picture. This is curing cancer and can be applied to other cancers. 14. BUYOUT.
0 · Reply
Latest News on PHIO
Phio Pharmaceuticals Announces Completion of Enrollment in Phase 1b Clinical Trial of INTASYL siRNA Lead Compound PH-762

Nov 25, 2025, 11:30 AM EST - 21 days ago

Phio Pharmaceuticals Announces Completion of Enrollment in Phase 1b Clinical Trial of INTASYL siRNA Lead Compound PH-762

Phio Pharmaceuticals Announces Upcoming Podium Presentation at the Advanced Therapies USA 2025 Congress

Nov 17, 2025, 8:45 AM EST - 4 weeks ago

Phio Pharmaceuticals Announces Upcoming Podium Presentation at the Advanced Therapies USA 2025 Congress

Phio Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 13, 2025, 4:15 PM EST - 4 weeks ago

Phio Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

Phio Pharmaceuticals to Present Recent Clinical Results from Skin Cancer Trial with siRNA based INTASYL PH-762

Nov 7, 2025, 10:30 AM EST - 5 weeks ago

Phio Pharmaceuticals to Present Recent Clinical Results from Skin Cancer Trial with siRNA based INTASYL PH-762

Phio Pharmaceuticals Announces INTASYL PH-762 is Named Immunomodulatory Solution of the Year in the BioTech Breakthrough Award Program

Nov 7, 2025, 7:45 AM EST - 5 weeks ago

Phio Pharmaceuticals Announces INTASYL PH-762 is Named Immunomodulatory Solution of the Year in the BioTech Breakthrough Award Program

Phio Pharmaceuticals Announces Exercise of Warrants for Approximately $13.4 Million Gross Proceeds

Nov 3, 2025, 1:40 PM EST - 6 weeks ago

Phio Pharmaceuticals Announces Exercise of Warrants for Approximately $13.4 Million Gross Proceeds

Phio Pharmaceuticals Announces Positive Pathology Results: Final Maximum Dose Cohort for INTASYL PH-762 Skin Cancer Trial

Nov 3, 2025, 7:45 AM EST - 6 weeks ago

Phio Pharmaceuticals Announces Positive Pathology Results: Final Maximum Dose Cohort for INTASYL PH-762 Skin Cancer Trial

Phio Pharmaceuticals Announces Appointment of Mr. David H. Deming to the Position of Lead Independent Director

Oct 31, 2025, 10:15 AM EDT - 6 weeks ago

Phio Pharmaceuticals Announces Appointment of Mr. David H. Deming to the Position of Lead Independent Director

Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series

Oct 21, 2025, 7:45 AM EDT - 2 months ago

Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series

Phio Pharmaceuticals to Present at the Life Sciences Future Conference

Sep 18, 2025, 7:45 AM EDT - 3 months ago

Phio Pharmaceuticals to Present at the Life Sciences Future Conference

Phio Pharmaceuticals to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Sep 3, 2025, 7:45 AM EDT - 3 months ago

Phio Pharmaceuticals to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Phio Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 14, 2025, 4:15 PM EDT - 4 months ago

Phio Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

Phio Pharmaceuticals Announces Exercise of Warrants for Approximately $2.5 Million Gross Proceeds

Jul 25, 2025, 3:04 PM EDT - 5 months ago

Phio Pharmaceuticals Announces Exercise of Warrants for Approximately $2.5 Million Gross Proceeds

Phio Pharmaceuticals Announces Pathology Results for Four of Five Patients in Fourth Cohort

Jul 25, 2025, 12:36 PM EDT - 5 months ago

Phio Pharmaceuticals Announces Pathology Results for Four of Five Patients in Fourth Cohort

Phio Pharmaceuticals Announces Agreement with U.S. Manufacturing Source for Drug Substance

Jul 25, 2025, 7:45 AM EDT - 5 months ago

Phio Pharmaceuticals Announces Agreement with U.S. Manufacturing Source for Drug Substance

Phio Pharmaceuticals Announces Positive Safety Monitoring Committee Recommendation to Advance INTASYL PH-762 Skin Cancer Clinical Trial to Fifth Dose Escalation Cohort

Jun 25, 2025, 7:45 AM EDT - 6 months ago

Phio Pharmaceuticals Announces Positive Safety Monitoring Committee Recommendation to Advance INTASYL PH-762 Skin Cancer Clinical Trial to Fifth Dose Escalation Cohort

Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series

Jun 24, 2025, 7:45 AM EDT - 6 months ago

Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series

Phio Pharmaceuticals Announces Strategic Initiative to Create Awareness of the Comprehensive INTASYL siRNA Portfolio

Jun 6, 2025, 7:45 AM EDT - 6 months ago

Phio Pharmaceuticals Announces Strategic Initiative to Create Awareness of the Comprehensive INTASYL siRNA Portfolio

Phio Pharmaceuticals Announces Participation in the Sidoti Micro-Cap Virtual Investor Conference

May 19, 2025, 7:45 AM EDT - 7 months ago

Phio Pharmaceuticals Announces Participation in the Sidoti Micro-Cap Virtual Investor Conference

Phio Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

May 15, 2025, 4:15 PM EDT - 7 months ago

Phio Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

Phio Pharmaceuticals Announces Positive Pathology Results in Third Cohort in INTASYL PH-762 Skin Cancer Clinical Trial

May 7, 2025, 7:45 AM EDT - 7 months ago

Phio Pharmaceuticals Announces Positive Pathology Results in Third Cohort in INTASYL PH-762 Skin Cancer Clinical Trial

Phio Pharmaceuticals Announces Positive Safety Monitoring Committee Recommendation to Advance INTASYL PH-762 Skin Cancer Study to Fourth Dose Escalation Cohort

Apr 9, 2025, 7:45 AM EDT - 8 months ago

Phio Pharmaceuticals Announces Positive Safety Monitoring Committee Recommendation to Advance INTASYL PH-762 Skin Cancer Study to Fourth Dose Escalation Cohort

Phio Pharmaceuticals Announces Podium Presentations on INTASYL siRNA Lead Product Candidates PH-762 and PH-894

Apr 3, 2025, 7:45 AM EDT - 9 months ago

Phio Pharmaceuticals Announces Podium Presentations on INTASYL siRNA Lead Product Candidates PH-762 and PH-894

Phio Pharmaceuticals Reports 2024 Year End Financial Results and Provides Business Update

Mar 31, 2025, 4:00 PM EDT - 9 months ago

Phio Pharmaceuticals Reports 2024 Year End Financial Results and Provides Business Update

American Academy of Dermatology Awards Podium Presentation to Phio Pharmaceutical's Clinical Research at 2025 Annual Meeting

Mar 10, 2025, 7:45 AM EDT - 10 months ago

American Academy of Dermatology Awards Podium Presentation to Phio Pharmaceutical's Clinical Research at 2025 Annual Meeting

Phio Pharmaceuticals Announces Completion of Enrollment in Third Safety Cohort in PH-762 Phase 1b Dose-Escalation Study

Mar 5, 2025, 7:45 AM EST - 10 months ago

Phio Pharmaceuticals Announces Completion of Enrollment in Third Safety Cohort in PH-762 Phase 1b Dose-Escalation Study

Phio Pharmaceuticals Announces Appointment of David H. Deming to Board of Directors

Feb 20, 2025, 7:45 AM EST - 10 months ago

Phio Pharmaceuticals Announces Appointment of David H. Deming to Board of Directors

Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series

Jan 22, 2025, 7:00 AM EST - 11 months ago

Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series

Phio Pharmaceuticals Announces Closing of $1.83 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jan 21, 2025, 4:15 PM EST - 11 months ago

Phio Pharmaceuticals Announces Closing of $1.83 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Phio Pharmaceuticals Announces $1.83 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jan 16, 2025, 1:00 PM EST - 11 months ago

Phio Pharmaceuticals Announces $1.83 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Phio Pharmaceuticals Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jan 15, 2025, 7:00 AM EST - 11 months ago

Phio Pharmaceuticals Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Phio Pharmaceuticals Announces $3.19 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jan 14, 2025, 7:00 AM EST - 1 year ago

Phio Pharmaceuticals Announces $3.19 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Cancer-Focused Phio Pharmaceuticals Stock Gains 300% On Monday - Here's Why

Jan 13, 2025, 12:45 PM EST - 1 year ago

Cancer-Focused Phio Pharmaceuticals Stock Gains 300% On Monday - Here's Why

Phio Pharmaceuticals Announces Promising Results of Second Cohort from Its Ongoing Clinical Study of PH-762

Jan 13, 2025, 7:45 AM EST - 1 year ago

Phio Pharmaceuticals Announces Promising Results of Second Cohort from Its Ongoing Clinical Study of PH-762

Phio Pharmaceuticals Announces Publication in Clinical, Cosmetic and Investigational Dermatology

Jan 2, 2025, 7:45 AM EST - 1 year ago

Phio Pharmaceuticals Announces Publication in Clinical, Cosmetic and Investigational Dermatology

Phio Pharmaceuticals Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Dec 23, 2024, 1:15 PM EST - 1 year ago

Phio Pharmaceuticals Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Phio Pharmaceuticals Announces $1.15 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Dec 19, 2024, 2:28 PM EST - 1 year ago

Phio Pharmaceuticals Announces $1.15 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Phio Pharmaceuticals Announces Positive Safety Monitoring Committee (SMC) Recommendation to Continue to Third Dose Cohort in its Clinical Study of PH-762

Dec 19, 2024, 7:45 AM EST - 1 year ago

Phio Pharmaceuticals Announces Positive Safety Monitoring Committee (SMC) Recommendation to Continue to Third Dose Cohort in its Clinical Study of PH-762

Phio Pharmaceuticals Announces Publication in Frontiers in Immunology

Dec 12, 2024, 9:21 AM EST - 1 year ago

Phio Pharmaceuticals Announces Publication in Frontiers in Immunology

Phio Pharmaceuticals is a Finalist for the Technology Disruptor of the Year Award

Dec 10, 2024, 7:45 AM EST - 1 year ago

Phio Pharmaceuticals is a Finalist for the Technology Disruptor of the Year Award

Phio Pharmaceuticals Announces Completion of Enrollment in Second Cohort in Phase 1b Dose-Escalating Clinical Study

Nov 19, 2024, 7:45 AM EST - 1 year ago

Phio Pharmaceuticals Announces Completion of Enrollment in Second Cohort in Phase 1b Dose-Escalating Clinical Study

Phio Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update

Nov 14, 2024, 5:47 PM EST - 1 year ago

Phio Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update

Phio Pharmaceuticals Announces Upcoming Presentation at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Nov 7, 2024, 10:00 AM EST - 1 year ago

Phio Pharmaceuticals Announces Upcoming Presentation at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Correction to Registration Link to Access Phio Pharmaceuticals' Presentation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series

Oct 18, 2024, 1:30 PM EDT - 1 year ago

Correction to Registration Link to Access Phio Pharmaceuticals' Presentation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series

Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-deal Roadshow Series

Oct 18, 2024, 8:00 AM EDT - 1 year ago

Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-deal Roadshow Series

Phio Pharmaceuticals Presenting Data on Its INSTAYL Compound PH-894 at ASGCT's 2024 Advancing Gene and Cell Therapies for Cancer Conference

Oct 16, 2024, 8:00 AM EDT - 1 year ago

Phio Pharmaceuticals Presenting Data on Its INSTAYL Compound PH-894 at ASGCT's 2024 Advancing Gene and Cell Therapies for Cancer Conference

Phio Announces Data Showcasing INTASYL's Role in Helping Immune Cells Target and Kill Cancer Cells

Oct 7, 2024, 8:00 AM EDT - 1 year ago

Phio Announces Data Showcasing INTASYL's Role in Helping Immune Cells Target and Kill Cancer Cells

INTASYL Technology and Compounds to be Focus of Presentation at 20th Annual Meeting of Oligonucleotide Therapeutics Society

Sep 25, 2024, 8:00 AM EDT - 1 year ago

INTASYL Technology and Compounds to be Focus of Presentation at 20th Annual Meeting of Oligonucleotide Therapeutics Society

Phio Pharmaceuticals Announces Presentation at the 9th Annual CAR-TCR Summit in Boston, MA

Sep 16, 2024, 8:00 AM EDT - 1 year ago

Phio Pharmaceuticals Announces Presentation at the 9th Annual CAR-TCR Summit in Boston, MA

Phio Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Sep 9, 2024, 7:00 AM EDT - 1 year ago

Phio Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference

DosGatos
DosGatos Dec. 16 at 6:37 PM
$PHIO Pumpers gone?
0 · Reply
DosGatos
DosGatos Dec. 16 at 6:37 PM
$PHIO one buck chuck!
0 · Reply
RetiredOldGeezer
RetiredOldGeezer Dec. 16 at 4:09 PM
$PHIO 12/16/25 Status from Clinical.gov site Still Recruiting - i thought that was completed? NCT06014086 Recruiting Intratumoral PH-762 for Cutaneous Carcinoma
0 · Reply
Tiredofbeingpoor
Tiredofbeingpoor Dec. 16 at 12:55 AM
$PHIO I think I’ll keep buying
0 · Reply
DosGatos
DosGatos Dec. 15 at 7:40 PM
$PHIO Below a buck?
1 · Reply
RetiredOldGeezer
RetiredOldGeezer Dec. 15 at 12:53 AM
$PHIO Old Bobby and his 3 babes have abandoned legacy holders - should have seen it coming when they put a wall street shark to head board - dead money but hopefully they are enjoying their our money.
0 · Reply
Stock__Hunter
Stock__Hunter Dec. 12 at 8:01 PM
$OCG pulled a $PHIO On ya
0 · Reply
PitaPierogi
PitaPierogi Dec. 12 at 2:49 PM
$PHIO https://x.com/i/status/1999201934797066382
0 · Reply
RetiredOldGeezer
RetiredOldGeezer Dec. 10 at 5:30 PM
$PHIO Are they still recruiting or was that a little fib?????
0 · Reply
PitaPierogi
PitaPierogi Dec. 9 at 11:26 PM
$PHIO big picture. This is curing cancer and can be applied to other cancers. 14. BUYOUT.
0 · Reply
PitaPierogi
PitaPierogi Dec. 9 at 2:52 PM
$PHIO silly
0 · Reply
DosGatos
DosGatos Dec. 8 at 10:39 PM
$PHIO
1 · Reply
KuruHabesha
KuruHabesha Dec. 8 at 7:52 PM
$PHIO Adding more
0 · Reply
RetiredOldGeezer
RetiredOldGeezer Dec. 8 at 6:48 PM
$PHIO I thought recruitment was complete - Gov Website says RECRUITING - Is it a scam or normal inefficiency? - I realize it is holidays and maybe the ladies are making cookies.
0 · Reply
DosGatos
DosGatos Dec. 8 at 6:15 PM
$PHIO El Scammo! Where my pumpers??
1 · Reply
RedDogSailor
RedDogSailor Dec. 8 at 4:24 PM
$PHIO Accumulation
0 · Reply
RetiredOldGeezer
RetiredOldGeezer Dec. 8 at 4:10 PM
$PHIO Think Old Man Bob and his 3 Babes got fleeced by the sharks.
0 · Reply
Bigmoney47
Bigmoney47 Dec. 8 at 3:50 PM
$PHIO why stock big stolen
0 · Reply
Astrid00
Astrid00 Dec. 8 at 3:10 PM
$PHIO 🔜📈
0 · Reply
Treechain
Treechain Dec. 4 at 6:29 PM
$PHIO action on the message boards, including Reddit apes
1 · Reply
ckruel
ckruel Dec. 4 at 3:37 PM
$PHIO the call for 2026 is to shift investing into health care, a sector that has been beaten down, as other sectors may suffer in a bearish 2026 market, finally we may see some positive movement in the bio sector.
0 · Reply
PitaPierogi
PitaPierogi Dec. 4 at 12:49 PM
$PHIO whispers of a buyout. 14+
0 · Reply